Adjuvant Chemotherapy and Prognostic Factors in XXXX - Izmir Oncology Group Study.

@entity1 @entity5 @entity1744 @entity1487 @entity34
BACKGROUND: Although adjuvant chemotherapy is a standard treatment in @entity5 , its benefit is not as clear for stage II @entity1 . In this retrospective analysis, we aimed to evaluate the survival of @entity1 with @entity5 , the efficacy of adjuvant chemotherapy in high-risk @entity5 @entity1 , and prognostic factors in @entity34 . MATERIALS AND METHODS: One hundred and seventeen @entity1 who were diagnosed with @entity5 between January 2006 and December 2011 were included in the study. @entity1 were stratified into two groups as being low-risk and high-risk according to risk factors for @entity34 . Adjuvant @entity1487 -based chemotherapy were administered to the @entity1 with risk factors. RESULTS: Ninety-four @entity1 were treated with adjuvant chemotherapy due to high risk factors and 23 were monitored without treatment. Median follow-up time was 43 months. In terms of disease free survival and overall survival, adjuvant chemotherapy did not provide a statistically significant difference. Univariate analysis demonstrated that @entity1744 was the major risk factor for shortened disease-free survival, while bowel perforation and perineural invasion were both negative prognostic factors for overall survival. CONCLUSIONS: The recommendation of adjuvant chemotherapy for @entity5 is not clear. In our study, it was found that adjuvant chemotherapy did not contribute to survival in high-risk stage II @entity1 . Due to the fact that prognosis of stage II @entity1 is good, many more @entity1 will be needed for statistically significant differences in survival. Adjuvant chemotherapy containing 5 @entity1487 is being used to high-risk stage II @entity1 although it is not a standard treatment approach.
